854PUpdated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)
Caffo, O, Palesandro, E, Nole, F, Gasparro, D, Mucciarini, C, Aieta, M, Zagonel, V, Iacovelli, R, Giorgi, U F F De, Rossetti, S, Fratino, L, Ermacora, P, Nicodemo, M, Giordano, M, Sartori, D, Scapoli,Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz248.011
Date:
October, 2019
File:
PDF, 73 KB
2019
File converter
More search results
More benefits 
